Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

AstraZeneca rated 'Strong Buy' after strong Q1 2026 revenue growth and promising drug data.

Company Fundamentals
24 May 2026
Seeking Alpha
View Source
Bullish
pluang ai news

AstraZeneca received a 'Strong Buy' rating following robust revenue growth in Q1 2026, driven by 16% and 15% increases in its Oncology and Rare Disease segments, respectively. Key drugs IMFINZI and ULTOMIRIS showed positive phase 3 trial results, opening new growth opportunities. The company exceeded Q1 estimates and confirmed its 2026 guidance, aiming for mid-to-high single-digit revenue growth and low double-digit EPS growth. This positions AstraZeneca as a promising investment in the biotech sector.

More News (AZN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App